Neurodegeneration research is moving rapidly from a search for one “best” biomarker toward combinations of fluid biomarkers that represent different aspects of disease biology. In Alzheimer’s disease alone, researchers can now investigate amyloid biology, phosphorylated tau, neuroaxonal injury, astrocytic responses and inflammation in blood or cerebrospinal fluid. At the same time, emerging biomarkers are expanding […]
As the landscape of Alzheimer’s disease (AD) research continues to evolve, there is increasing demand for blood-based biomarkers that offer both precision and scalability. Among these, brain-derived phosphorylated tau (BDpTau) markers are gaining momentum for their unique ability to measure tau proteins sourced exclusively from the brain. These biomarkers address a critical limitation of conventional […]




















